Allogeneic Hematopoietic Cell Transplantation in First Remission Abrogates Poor Outcomes Associated with High-Risk Pediatric Acute Myeloid Leukemia

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 7, 2013, Pages 1021-1025

  Burke, Michael J ^a   Wagner, John E ^a   Cao, Qing ^b   Ustun, Celalettin ^a   Verneris, Michael R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Acute myeloid leukemia (AML); High risk; Transplantation pediatric

Indexed keywords

CD135 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; ITD PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CHROMOSOME 11Q; CHROMOSOME 5; CHROMOSOME 7; DISEASE ASSOCIATION; FEMALE; GENE REARRANGEMENT; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; SURVIVAL; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; MYELOABLATIVE AGONISTS; ONCOGENE PROTEINS, FUSION; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RISK; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84879339630     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.04.001     Document Type: Article

References (36)

1. Pui C.H., Mullighan C.G., Evans W.E., Relling M.V. Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there?. Blood 2012, 120:1165-1174.
2. Pui C.H., Carroll W.L., Meshinchi S., Arceci R.J. Biology, risk stratification, and therapy of pediatric acute leukemias: An update. JClin Oncol 2011, 29:551-565.
3. Woods W.G. Curing childhood acute myeloid leukemia (AML) at the half-way point: Promises to keep and miles to go before we sleep. Pediatr Blood Cancer 2006, 46:565-569.
4. Horan J.T., Alonzo T.A., Lyman G.H., et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: The Children's Oncology Group. JClin Oncol 2008, 26:5797-5801.
5. Hospital M.A., Thomas X., Castaigne S., et al. Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML. Bone Marrow Transplant 2012, 47:1436-1441.
6. Wheatley K., Burnett A.K., Goldstone A.H., et al. Asimple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999, 107:69-79.
7. Riley L.C., Hann I.M., Wheatley K., Stevens R.F. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br J Haematol 1999, 106:436-444.
8. Meshinchi S., Arceci R.J. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist 2007, 12:341-355.
9. Harrison C.J., Hills R.K., Moorman A.V., et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. JClin Oncol 2010, 28:2674-2681.
10. Gibson B.E., Wheatley K., Hann I.M., et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005, 19:2130-2138.
11. Reinhardt D., Kremens B., Zimmermann M., et al. No improvement of overall-survival in children with high-risk acute myeloid leukemia by stem cell transplantation in 1st complete remission. [ASH Annual Meeting Abstracts] Blood 2006, 108:320.
12. Niewerth D., Creutzig U., Bierings M.B., Kaspers G.J. Areview on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 2010, 116:2205-2214.
13. Meshinchi S, Alonzo T, Gerbing RB, etal. Minimal residual disease detection by four-color multidimensional flow cytometry identifies pediatric AML patients at high risk of relapse. [ASH Annual Meeting Abstracts] Blood. 2007;110:1429.
14. Kaplan EL MP. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
15. Lin D.Y. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997, 16:901-910.
16. Majhail N.S., Brazauskas R., Hassebroek A., et al. Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia. Biol Blood Marrow Transplant 2012, 18:861-873.
17. Woods W.G., Kobrinsky N., Buckley J., et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: A Childrens Cancer Group pilot study. JClin Oncol 1993, 11:1448-1457.
18. Dini G., Boni L., Abla O., et al. Allogeneic bone marrow transplantation in children with acute myelogenous leukemia in first remission. Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO). Bone Marrow Transplant 1994, 13:771-776.
19. Klingebiel T., Pession A., Paolucci P., Rondelli R. Autologous versus allogeneic BMT in AML: The European experience. Report of the EBMT-Pediatric Diseases Working Party. Bone Marrow Transplant 1996, 18(Suppl 2):49-52.
20. Zwaan C.M., Meshinchi S., Radich J.P., et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: Prognostic significance and relation to cellular drug resistance. Blood 2003, 102:2387-2394.
21. Creutzig U., Zimmermann M., Ritter J., et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005, 19:2030-2042.
22. Koh K.N., Park M., Kim B.E., et al. Favorable outcomes after allogeneic hematopoietic stem cell transplantation in children with high-risk or advanced acute myeloid leukemia. JPediatr Hematol Oncol 2011, 33:281-288.
23. Beck J.C., Cao Q., Trotz B., et al. Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. Bone Marrow Transplant 2011, 46:950-955.
24. Nemecek E.R., Ellis K., He W., et al. Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission. Biol Blood Marrow Transplant 2011, 17:1833-1840.
25. Borgmann A., Baumgarten E., Schmid H., et al. Allogeneic bone marrow transplantation for a subset of children with acute lymphoblastic leukemia in third remission: A conceivable alternative?. Bone Marrow Transplant 1997, 20:939-944.
26. Gassas A., Ishaqi M.K., Afzal S., et al. Acomparison of the outcomes of children with acute myelogenous leukemia in either first or second complete remission (CR1 vs CR2) following allogeneic hematopoietic stem cell transplantation at a single transplant center. Bone Marrow Transplant 2008, 41:941-945.
27. Bunin N.J., Davies S.M., Aplenc R., et al. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. JClin Oncol 2008, 26:4326-4332.
28. Lee D.H., Kwon Y.J., Lim J., et al. Comparable outcomes of HLA-matched unrelated and HLA-identical sibling donor bone marrow transplantation for childhood acute myeloid leukemia in first remission. Pediatr Transplant 2009, 13:210-216.
29. Smith A.R., Baker K.S., Defor T.E., et al. Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: Similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors. Biol Blood Marrow Transplant 2009, 15:1086-1093.
30. Eapen M., Rubinstein P., Zhang M.J., et al. Outcomes of transplantation ofunrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: A comparison study. Lancet 2007, 369:1947-1954.
31. Zhang M.J., Davies S.M., Camitta B.M., et al. Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2012, 18:1204-1210.
32. Harvey J., Green A., Cornish J., et al. Improved survival in matched unrelated donor transplant for childhood ALL since the introduction of high-resolution matching at HLA class I and II. Bone Marrow Transplant 2012, 47:1294-1300.
33. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. NEngl J Med 2010, 363:2091-2101.
34. Walter R.B., Gooley T.A., Wood B.L., et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. JClin Oncol 2011, 29:1190-1197.
35. Venditti A., Maurillo L., Buccisano F., et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia 2003, 17:2178-2182.
36. Laane E., Derolf A.R., Bjorklund E., et al. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica 2006, 91:833-836.